Jane Street’s Atara Biotherapeutics ATRA Stock Holding History

Jane Street’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-624	Closed	-$122K	–	9662
2022 Q2	$122K	Sell	624 -172	-22%	-$28.1K	﹤0.01%	8527
2022 Q1	$185K	Sell	796 -36	-4%	-$11.5K	﹤0.01%	9085
2021 Q4	$328K	Buy	832 +424	+104%	+$178K	﹤0.01%	8005
2021 Q3	$183K	Buy	+408	New	+$146K	﹤0.01%	8919
2021 Q1	–	Sell	-580	Closed	-$285K	–	9062
2020 Q4	$285K	Buy	+580	New	+$268K	﹤0.01%	6486
2018 Q2	–	Sell	-704	Closed	-$686K	–	4947
2018 Q1	$686K	Buy	+704	New	+$642K	﹤0.01%	3115

Other funds holding ATRA

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jane Street's ATRA Position: Q1 2026 in Review

Jane Street increased its Atara Biotherapeutics (ATRA) stake by 142% in Q1 2026, buying an estimated $121K and bringing the position to 33,870 shares worth $160K. The position accounts for ﹤0.01% of the portfolio, ranked #10334.

Jane Street first reported a position in ATRA in Q3 2015 and has held it in 21 quarters since. The position peaked at $1.4M in Q3 2020. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

Jane Street held 33,870 shares of Atara Biotherapeutics worth $160K as of Q1 2026.
Jane Street bought 19,880 Atara Biotherapeutics shares in Q1 2026, an estimated $121K.
Atara Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10334 holding.
Jane Street first reported a position in Atara Biotherapeutics in Q3 2015 and has held it in 21 quarters since.
Jane Street's Atara Biotherapeutics position peaked at $1.4M in Q3 2020.
33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.